A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)

About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma (HCC)
Eligibility Criteria
Inclusion Criteria: Diagnosis of hepatocellular carcinoma (HCC) ≥ 2cm based on: Biopsy OR Radiological evidence of HCC by contrast-enhanced CT scan or contrast-enhanced AND Blood test positive for Hepatitis B or C AND Alpha fetoprotein above > 400 mg/L Not appropriate for curative surgery Screening Blood Pressure <150/100 mmHg, Left Ventricular Ejection Fraction (LVEF) >50% Exclusion Criteria: Heart Attack within 12 months, uncontrolled chest pain within 6 months Ascites resistant to diuretic medication therapy Portal-systemic encephalopathy Portal hypertension with bleeding esophageal or gastric varices within the past 2 months Deficiency of sodium in the blood with sodium < 125 mEq/L Subjects with serious non-healing wounds, ulcers or bone fractures
Sites / Locations
- City Of Hope National Medical Center
- Harbor-Ucla Medical Center
- Christiana Care Health Services
- University Of Miami Miller School Of Medicine
- Northwestern University Feinberg School Of Medicine
- University Of Chicago
- University Of Iowa Hospitals And Clinics
- Wayne State University
- The Cancer Center At Hackensack University Medical Center
- Duke University Medical Center
- Penn State Milton S. Hershey Medical Center
- Albert Einstein Cancer Center
- Univ Of Texas Southwestern
- Md Anderson Cancer Center
- Medical College Of Wisconsin
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
Arms of the Study
Arm 1
Experimental
1
no comparator to brivanib